《COVID-19 疫苗的现状。范围综述》。
The current status of COVID-19 vaccines. A scoping review.
机构信息
Biomedical Group (BIO277), Department of Nursing, Faculty of Health Sciences, University of Granada, Avda. Ilustración 60, 18016 Granada, Spain; Institute of Biosanitary Research, Ibs.Granada, C/ Doctor Azpitarte 4, 4a Planta, 18012 Granada, Spain.
Institute of Biosanitary Research, Ibs.Granada, C/ Doctor Azpitarte 4, 4a Planta, 18012 Granada, Spain; Biomedical Group (BIO277), Department of Nursing, Faculty of Health Sciences of Ceuta, University of Granada, C/ Cortadura del Valle, Sn, 51001 Ceuta, Spain.
出版信息
Drug Discov Today. 2022 Nov;27(11):103336. doi: 10.1016/j.drudis.2022.08.004. Epub 2022 Aug 19.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new disease that has led to a worldwide pandemic, resulting in millions of deaths and a high economic burden. Here, we analyze the current status of preventive vaccines authorized by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). Published clinical trials have shown the effectiveness of mRNA (BNT162b2 and Spikevax), adenovirus vector-based (Ad26.COV2.S and ChAdOx1 nCoV-19), and recombinant protein S (NVX-CoV2373) vaccines to be between 52.9% and 100%. The most-frequent adverse effects include local pain, fatigue, headache, or chills. Serious events are associated with Ad26.COV2.S and ChAdOx1 nCoV-19 vaccines.
严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）是一种新出现的疾病，已导致全球大流行，造成数百万人死亡和巨大的经济负担。在这里，我们分析了欧洲药品管理局（EMA）和美国食品和药物管理局（FDA）批准的预防疫苗的现状。已发表的临床试验表明，mRNA（BNT162b2 和 Spikevax）、腺病毒载体（Ad26.COV2.S 和 ChAdOx1 nCoV-19）和重组蛋白 S（NVX-CoV2373）疫苗的有效性在 52.9%至 100%之间。最常见的不良反应包括局部疼痛、疲劳、头痛或寒战。Ad26.COV2.S 和 ChAdOx1 nCoV-19 疫苗与严重事件有关。
Zotero 插件